Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial



    CALGARY, Aug. 11 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC,
NASDAQ:  ONCY) has completed patient enrolment in the dose escalation portion of
its U.K. clinical trial to evaluate the anti-tumour effects of systemic
administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in
patients with advanced cancers including bladder, prostate, lung and upper
gastro-intestinal. The principal investigator is Professor Hardev Pandha of
the Royal Surrey Hospital, U.K.
    The trial (REO 010) has two components. The first is an open-label,
dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with
docetaxel every three weeks. Standard dosages of docetaxel were delivered to
patients with escalating dosages of REOLYSIN(R) intravenously. The second
component of the trial includes the enrolment of a further nine patients at
the top dose of REOLYSIN(R) in combination with a standard dosage of
docetaxel.
    "We have completed the dose escalation stage of the study," said Prof.
Pandha. "Patients enrolled had previously undergone significant treatment with
combination chemotherapy. The combination of REOLYSIN(R) and taxotere was
safe, well tolerated with no obvious toxicity related specifically to
REOLYSIN(R). Efficacy of the combination was encouraging: both objective
anti-tumour responses and disease stabilization were observed radiologically."
    Eligible patients include those who have been diagnosed with advanced or
metastatic solid tumours including bladder, lung, prostate or upper
gastro-intestinal cancers that are refractory (have not responded) to standard
therapy or for which no curative standard therapy exists. The primary
objective of the trial is to determine the Maximum Tolerated Dose (MTD),
Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety
profile of REOLYSIN(R) when administered in combination with docetaxel.
Secondary objectives include the evaluation of immune response to the drug
combination, the body's response to the drug combination compared to
chemotherapy alone and any evidence of anti-tumour activity.

    About Oncolytics Biotech Inc.

    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com
    For more information about docetaxel (taxotere(R)) please visit
www.taxotere.com

    This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the U.K. combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial and
the Company's belief as to the potential of REOLYSIN(R) as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the
tolerability of REOLYSIN(R) outside a controlled test, the success and timely
completion of clinical studies and trials, the Company's ability to
successfully commercialize REOLYSIN(R), uncertainties related to the research
and development of pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these forward-looking
statements.

    %SEDAR: 00013081E




For further information:

For further information: Oncolytics Biotech Inc., Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward@oncolytics.ca; The Equicom Group, Nick Hurst, 325, 300
5th Ave. SW, Calgary, AB, T2P 3C4, Tel: (403) 538-4845, Fax: (403) 237-6916,
nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran, 11 Stone
St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,
emoran@investorrelationsgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890